Advances in the molecular dissection of inflammatory bowel disease

Seminars in Immunology

Volumn 18, Issue 4, 2006, Pages 244-253

  Siminovitch, Katherine Anne ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Genetic determinants; Inflammatory bowel disease; Polymorphisms

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; PROTEIN; SLC22A4 PROTEIN; SLC22A5 PROTEIN; UNCLASSIFIED DRUG;

CROHN DISEASE; ENTERITIS; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; MEMBRANE PROTEINS; NOD2 SIGNALING ADAPTOR PROTEIN; ORGANIC CATION TRANSPORT PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 33745252006     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2006.03.012     Document Type: Review

References (160)

1. Loftus Jr. E.V. Clinical epidemiology of inflammatory disease: incidence, prevalence and environmental influences. Gastroenterology 126 (2004) 1504-1517
2. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
3. Sartor R.B. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 92 (1997) 55-115
4. Bouma G., and Strober W. The immunological and genetic bases of inflammatory bowel disease. Nat Rev Immunol 3 (2003) 521-533
5. + lamina propria (LP) lymphocyte secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas, ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157 (1996) 1261-1270
6. Monteleone G., Biancone L., Marasco R., Luzza F., and Pallone F. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112 (1997) 1169-1178
7. Neurath M.F. Mucosal immunity in Crohn's disease. Inflamm Bowel Dis 10 (2004) 529-531
8. Tsukada Y., Nakamura T., Iimura M., Iizuko B.E., and Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol 97 (2002) 2820-2828
9. Sartor R.B. The influence of normal bacterial flora in the development of chronic mucosal inflammation. Res Immunol 148 (1997) 467-476
10. Rath H.C., Schultz M., Freitag R., Dieleman L.A., Li F., Linde H.J., et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 61 (2001) 2277-2285
11. Strober W., Fuss I.J., and Blumberg R.S. The immunology of mucosal models of inflammation. Annu Rev Immunol 20 (2002) 495-549
12. Tysk C., Lindberg E., Jarnerot G., and Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monocytic and dizygotic twins. A study of heritability and the influence of smoking. Gut 29 (1988) 990-996
13. Orholm M., Binder V., Sorensen T.I., Rasmussen L.P., and Kyvik K.O. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scan J Gastroenteral 35 (2000) 1075-1081
14. Thompson N.P., Driscoll R., Pounder R.E., and Wakefield A.J. Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ 312 (1996) 95-96
15. Mayberry J.F., Rhodes J., and Newcombe R.G. Familial prevalence of inflammatory bowel disease in relatives of patients with Crohn's disease. BMJ 280 (1980) 84
16. Roth M.P., Petersom G.M., McElree C., Vadheim C.M., Panish J.F., and Rotter J.I. Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenertol 96 (1989) 1016-1020
17. Probert C.S.J., Jayanthi V., Hughes A.O., Thompson J.R., Wicks C.A.N., and Mayberry J.F. Prevalence and family risk of ulcerative colitis and Crohn's disease-an epidemiologic study among Europeans and South Asians in Leicestershire. Gut 34 (1993) 1547-1551
18. Yang H., McElree C., Roth M.P., Shanahan F., Targan S.R., and Rotter J.I. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 34 (1993) 517-524
19. Satsangi J., Rosenberg W.M.C., and Jewell D.P. The prevalence of inflammatory bowel disease in relative of patients with Crohn's disease. Eur J Gastro Hepat 6 (1994) 413-416
20. Weterman I.T., and Pena A.S. Familial incidence of Crohn's disease in the Netherlands and a review of the literature. Gastroenterology 111 (1996) 604-607
21. Orholm M., Munkholm P., Langholz E., Nielsen O.H., Sorensen I.A., and Binder V. Familial occurrence of inflammatory bowel disease. New Engl J Med 324 (1991) 94-98
22. Meucci G., et al. Familial aggregation of inflammatory bowel disease in northern Italy: a multicenter study. The Gruppo di Studio per le Malattie Infliammatorie Intestinali. Gastroenterology 103 (1992) 514-519
23. Lashner B.A., Evans A.A., Kirsner J.B., and Hanauer S.B. Prevalence and incidence of inflammatory bowel disease in family members. Gastroenterology 91 (1986) 1396-1400
24. Monsen U., Brostrom O., Nordenvall B., Sorstad J., and Hellers G. Prevalence of inflammatory bowel disease among relatives of patients with ulcerative colitis. Scan J Gastroenterol 22 (1987) 214-218
25. Annese V., et al. Clinical features in familial cases of Crohn's disease and ulcerative colitis in Italy: a GISC study. Amer J Gastroenterol 96 (2001) 2939-2945
26. Peeters M., Nevens H., Baert F., Hiele M., de Meyer A.M., Vlietinck R., et al. Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastrolenterol 111 (1996) 597-603
27. Satsangi J., Grootscholten C., Holt H., and Jewell D. Clinical patterns of familial inflammatory bowel disease. Gut 38 (1996) 738-741
28. Hugot J.P., Laurent-Puig P., Gower-Rousseau C., Olson J.M., Lee J.C., Beaugerie L., et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 379 (1996) 821-823
29. Satsangi J., Parkes M., Louis E., Hashimoto L., Kato N., Welsh K., et al. Two-stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 14 (1996) 199-202
30. Cho J.H., Nicolae D.L., Gold L.H., Fields C.T., LaBuda M.C., Rohal P.M., et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci USA 95 (1998) 7502-7507
31. Ma Y., Ohmen J.D., Li Z., Bentley L.G., McElree C., Pressman S., et al. A genome wide search identifies potential new susceptibility loci for Crohn's disease. Inflamm Bowel Dis 5 (1999) 271-278
32. Hampe J., Schreiber S., Shaw S.H., Lau K.F., Bridger S., Macpherson A.J., et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet 64 (1999) 808-816
33. Rioux J.D., Silverberg M.S., Daly M.S., Steinhart A.H., McLeod R.S., Griffiths A.M., et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 66 (2000) 1863-1870
34. Duerr R.H., Barmada M.M., Zhang L., Pfutzer R., and Weeks D.E. High-density genome scan in Crohn's disease shows confirmed linkage to chromosome 14q11-12. Am J Hum Genet 66 (2000) 1857-1862
35. Paavola-Sakki P., Ollikainen V., Helio T., Halme L., Turunen U., Lahermo P., et al. Genome-wide search in Finnish families with inflammatory bowel disease provides evidence for novel susceptibility loci. Eur J Hum Genet 11 (2003) 112-120
36. Barmada M.M., Brant S.R., Nicolae D.L., Achkar J.P., Panhuysen C.I., Bayless T.M., et al. A genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm Bowel Dis 10 (2004) 15-22
37. Vermeire S., Rutgeerts P., Van Steen K., Joossens S., Claessens G., Pierik M., et al. Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis. Gut 53 (2004) 980-986
38. Cavanaugh J. International collaboration provides convincing linkage replication in complex disease though analysis of a large pooled data set: Crohn's disease and chromosome 16. Amer J Hum Genet 68 (2001) 1165-1171
39. Williams C.N., Kocher K., Lander E.S., Daly M.J., and Rioux J.D. Using a genome-wide scan and meta-analysis to identify IBD loci. Inflamm Bowel Dis 8 (2002) 375-381
40. van Heel D.A., Fisher S.A., Kirby A., Daly M.J., Rioux J.D., Lewis C.M., et al. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet 13 (2004) 763-770
41. Risch N., and Merikangas K. The future of genetic studies of complex human diseases. Science 273 (1996) 1516-1517
42. Sachidanadam R., Weissman D., Schmidt S.C., Kakol J.M., Stein L.D., Marth G., et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409 (2001) 928-933
43. Altshuler D., Brooks L.D., Chakravarti A., Collins F.S., Daly M.J., Donnelly P., et al. A haplotype map of the human genome. Nature 437 (2005) 1299-1320
44. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
45. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
46. Hampe J., Cuthbert A., Croucher P.J., Mirza M.M., Mascheretti S., Fisher S., et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 357 (2001) 1925-1928
47. Vermeire S., Wild G., Kocher K., Cousineau J., Dufresne L., Bitton A., et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 71 (2002) 74-83
48. Cuthbert A.P., Fisher S.A., Mirza M.M., King K., Hampe J., Croucher P.J., et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 122 (2002) 867-874
49. Hampe J., Grebe J., Nikolaus S., Solberg C., Croucher P.J., Mascheretti S., et al. Association of NOD2 (CARD15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 359 (2002) 1661-1665
50. Lesage S., Zouali H., Cezard J.P., Colombel J.F., Belaiche J., Almer S., et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 70 (2002) 845-857
51. Cavanaugh J.A., Adams K.E., Quak E.J., Bryce M.E., O'Callaghan N.J., Rodgers H.J., et al. CARD15/NOD2 risk alleles in the development of Crohn's disease in the Australian population. Ann Hum Genet 67 (2003) 35-41
52. Newman B., Silverberg M.S., Gu X., Zhang Q., Lazaro A., Steinhart A.H., et al. CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn's disease. Am J Gastroenterol 99 (2004) 306-315
53. Helio T., Halme L., Lappalainen M., Fodstad H., Paavola-Sakki P., Turunen U., et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut 52 (2003) 558-562
54. Bairead E., Harmon D.L., Curtis A.M., Kelly Y., O'Leary C., Gardner M., et al. Association of NOD2 with Crohn's disease in a homogeneous Irish population. Eur J Hum Genet 11 (2003) 237-244
55. Kugathasan S., Loizides A., Babusukumar U., McGuire E., Wang T., Hooper P., et al. Comparative phenotypic and CARD15 mutational analysis among African-American, Hispanic, and white children with Crohn's disease. Inflamm Bowel Dis 11 (2005) 631-638
56. Inoue N., Tamura K., Kinouchi Y., Fukuda Y., Takahashi S., Orgura Y., et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 123 (2002) 86-91
57. Leong R.W., Armuzzi A., Ahmad T., Wong M.L., Tse P., Jewell D.P., et al. NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population. Aliment Pharmacol Ther 17 (2003) 1465-1470
58. Croucher P.J., Mascheretti S., Hampe J., Huse K., Frenzel H., Stoll M., et al. Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet 11 (2003) 6-16
59. Economou M., Trikalinos T.A., Loizou K.T., Tsianos E.V., and Ioannidis J.P. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a meta-analysis. Am J Gastroenterol 99 (2004) 2393-2404
60. Annese V., Lombardi G., Perri F., D'Inca R., Ardizzone S., Riegler G., et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease-an IG-IBD study. Am J Gastroenterol 100 (2005) 84-92
61. Abreu M.T., Taylor K.D., Li Y.C., Hang T., Gaiennie J., Landers C.J., et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 123 (2002) 679-688
62. Alvarez-Lobos M., Arostegui J.I., Sans M., Tassies D., Plaza S., Delgado S., et al. Crohn's disease patients carrying NOD2/CARD15 gene variants have an increased and early need for first surgery due to structuring disease and higher rate of surgical recurrence. Ann Surg 242 (2005) 693-700
63. Vermeire S., Louis E., Rutgeerts P., De Vos M., Van Gossum A., Belaiche J., et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 123 (2002) 106-111
64. Mascheretti S., Hampe J., Croucher P.J., Nikolaus S., Andus T., Schubert S., et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetic 12 (2002) 509-515
65. Inohara N., Chamaillard M., McDonald C., and Nunez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 74 (2005) 355-383
66. Harton J.A., Linhoff M.W., Zhang J., and Ting J.P. Cutting edge: CATERPILLAR: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding and leucine-rich repeat domains. J Immunol 169 (2002) 4088-4093
67. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 1 (2001) 135-145
68. Akira S., and Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 85 (2003) 85-95
69. Ogura Y., Inohara N., Benito A., Chen F.F., Yamaoka S., and Nunez G. Nod2, a Nod 1/Apaf1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 276 (2001) 4812-4818
70. Gutierrez O., Pipaon C., Inohara N., Fontaiba A., Ogura Y., Prosper G., et al. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. J Biol Chem 277 (2002) 41701-41705
71. Lala S., Ogura Y., Osborne C., Hor S.Y., Bromfield A., Davies S., et al. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 125 (2003) 47-57
72. Rosenstiel P., Fantini M., Brautigam K., Kuhbacher T., Waetzig G.H., Seegert D., et al. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 124 (2003) 1001-1009
73. Hisamatsu T., Suzuki M., Reinecker H.C., Nadeau W.J., McCormick B.A., and Podolsky D.K. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124 (2003) 993-1000
74. Girardin S.E., Boneca I.G., Viala J., Chamaillard M., Labigne A., Thomas G., et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278 (2003) 8869-8872
75. Polanski M., and Gray G.R. Incorporation of bacterial peptidoglycan constituents into macrophage lipids during phagocytosis. J Immunol 143 (1989) 2706-2713
76. Inamura S., Kusumoto S., Hashimoto M., Gutierrez O., Pons F., Crespo J., et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 278 (2003) 5509-5512
77. Vavricka S.R., Musch M.W., Chang J.E., Nakagawa Y., Phanvijhitsiri K., Waypa T.S., et al. hPepT1 transports muramyl dipeptide, activating NF-kappaB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology 127 (2004) 1401-1409
78. Tanabe T., Chamaillard M., Ogura Y., Zhu L., Qui S., Masumoto J., et al. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J 23 (2004) 1587-1597
79. Ogura Y., Inohara N., Benito A., Chen F.F., Yamaoka S., and Nunez G. Nod2, a Nod1/Apaf-1-family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 276 (2001) 4812-4818
80. Chin A.I., Dempsey P.W., Bruhn K., Miller J.F., Xu Y., and Cheng G. Involvement of receptor-interacting protein 2 in innate and adaptive immune responses. Nature 416 (2002) 190-194
81. Kobayashi K., Inohara N., Hernandez L.D., Galan J.E., Nunez G., Janeway C.A., et al. RICK/Rip2/CARDIAK mediates signaling for receptors of the innate and adaptive immune systems. Nature 416 (2002) 194-199
82. Navas T.A., Baldwin D.T., and Stewart T.A. RIP2 is a Raf1-activated mitogen-activated protein kinase. J Biol Chem 274 (1999) 33684-33690
83. Pauleau A.L., and Murray P.J. Role of nod2 in the response of macrophages to toll-like receptor agonists. Mol Cell Biol 23 (2003) 7531-7539
84. Barnich N., Aguirre J.E., Reinecker H.-C., Xavier R., and Podolsky D.K. Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-kβ activation in muramyl dipeptide recognition. J Cell Biol 170 (2005) 21-26
85. Berrebi D., Maudinas R., Hugot J.P., Chamaillard M., Chareyre F., De Lagausie C., et al. Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. Gut 52 (2003) 840-846
86. Schreiber S., Nikolaus S., and Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 42 (1997) 477-484
87. Chamaillard M., Philpott D., Girardin S.E., Zouali H., Lesage S., Chareyre F., et al. Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci USA 100 (2003) 3455-3460
88. Kobayashi K., Chamaillard M., Ogura Y., Henegariu O., Inohara N., Nunez G., et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307 (2005) 731-734
89. Maeda S., Hsu L.C., Liu H., Bankston L.A., Iimure M., Kagnoff M.F., et al. Nod2 mutation in Crohn's disease potentiates NF-κB activity and IL-1beta processing. Science 307 (2005) 734-738
90. Watanabe T., Kitani A., Murray P.J., and Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 5 (2004) 800-808
91. Netea M.G., Kullberg B.J., de Jong D., Franke B., Sprong T., Naber T.H., et al. NOD2 mediates induction of the inflammatory signals induced by TLR2-ligands: implications for Crohn's disease. Eur J Immunol 34 (2004) 2052-2059
92. van Heel D.A., Ghosh S., Hunt K., Hunt K.A., Lundberg A.M., Ahmad T., et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 365 (2005) 1794-1796
93. Netea M.G., Ferwerda G., de Jong D.J., Girardin S.E., Kullberg B.J., and van der Meer J.W.M. NOD2 3020insC mutation and the pathogenesis of Crohn's disease: impaired IL-Iβ production points to a loss-of-function phenotype. Neth J Med 63 (2005) 305-308
94. Voss E., Wehkamp J., Wehkamp K., Stange E.F., Schroder J.M., and Harder J. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem 281 (2006) 2005-2011
95. Buhner S., Buning C., Genschel J., Kling K., Hermann D., Dignass A., et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation. Gut 55 (2006) 341-347
96. Rioux J.D., Daly M.J., Silverberg M.S., Lindblad K., Steinhart H., Cohen Z., et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn's disease. Nat Genet 29 (2001) 223-228
97. Negoro K., McGovern D.P., Kinouchi Y., Takahashi S., Lench N.J., Shimosegawa T., et al. Analysis of the IBD5 locus and potential gene-gene interactions in Crohn's disease. Gut 52 (2003) 541-546
98. Armuzzi A., Ahmad T., Ling K.L., de Silva A., Cullen S., van Heel D., et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 52 (2003) 1133-1139
99. Mirza M.M., Fisher S.A., King K., Cuthbert A.P., Hampe J., Sanderson J., et al. Genetic evidence for interaction of the 5q31 cytokine locus and the CARD15 gene in Crohn's disease. Am J Hum Genet 72 (2003) 1018-1022
100. Giallourakis C., Stoll M., Miller K., Hampe J., Lander E.S., Daly M.J., et al. IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn's disease and identification of a novel association with ulcerative colitis. Am J Hum Genet 73 (2003) 205-211
101. McGovern D.P.B., van Heel D.A., Negoro K., Ahmed T., and Jewell D.P. Further evidence of IBD5/CARD15 (NOD2) epistasis in the susceptibility to ulcerative colitis. Am J Genet 73 (2003) 1465-1466
102. Peltekova V.D., Wintle R.F., Rubin L.A., et al. Functional variants in the SLC22A4 and SLC22A5 genes that are associated with Crohn's disease. Nat Genet 36 (2004) 471-475
103. Newman B., Gu X., Wintle R., Cescon D., Yazdanpanah M., Liu X., et al. A risk haplotype in the solute carrier family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's disease. Gastroenterology 128 (2005) 260-269
104. Burckhardt G., and Wolff N.A. Structure of renal organic anion and cation transporters. Am J Physiol Renal Physiol 278 (2000) F853-F866
105. Wu X., Huang W., Prasad P.D., Seth P., Rajan D.P., Leibach F.H., et al. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), and organic cation/carnitine transporter. J Pharmacol Exp Ther 290 (1999) 1482-1492
106. Noble C.L., Nimmo E.R., Drummond H., Ho G.T., Tenesa A., Smith L., et al. The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease. Gastroenterology 129 (2005) 1854-1864
107. Torok H.-P., Glas J., Lonenchi L., Lohse P., Muller-Myhsok B., Limbersky O., et al. Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. Gut 54 (2005) 1421-1427
108. Waller S, Tremelling M, Bredin F, Godfrey L, Howson J, Parkes M. Evidence for association of OCTN genes and IBD5 with ulcerative colitis. Gut 2005 16; online.
109. Tosa M., Negoro K., Kinouchi Y., Abe H., Nomura E., Takagi S., et al. Lack of association between IBD5 and Crohn's disease in Japanese patients demonstrates population-specific differences in inflammatory bowel disease. Scan J Gastroenterol 41 (2006) 48-53
110. Martinez A., Martin M.D.C., Mendoza J.L., Taxonera C., Diaz-Rubio M., de la Concha E.G., et al. Association of the organic cation transporter OCTN genes with Crohn's disease in the Spanish population. Eur J Hum Genet 14 (2006) 222-226
111. Vermeire S., Pierik M., Hlavaty T., Claessens G., Van Schuerbreek N., Joossens S., et al. Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD. Gastroenterology 129 (2005) 1845-1853
112. Ho P., Bruce I.N., Silman A., Symmons D., Newman B., Young H., et al. Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthr Rheum 52 (2005) 3596-3602
113. Tokuhiro S., Yamada R., Chang X., Suzuki A., Kochi Y., Sawada T., et al. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 35 (2003) 341-348
114. Ohashi R., Tamai I., Jun-Ichi N., Nikaido H., Hashimoto N., Oku A., et al. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharm 59 (2001) 358-366
115. van Monfoort J.E., Hagenbuch B., Groothuis G.M.M., Koepsell H., Meier P.J., and Meijer D.K.F. Drug uptake systems in liver and kidney. Curr Drug Metab 4 (2003) 185-211
116. Treem W.R., Stanley C.A., Finegold D.N., Hale D.E., and Coates P.M. Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts. N Engl J Med 17 (1988) 1331-1336
117. Roediger W.E., and Nance S. Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation. Br J Exp 67 (1986) 773-782
118. Grundemann D., Harlfinger S., Golz S., Geerts A., Lazar A., Berkels R., et al. Discovery of the ergothioneine transporter. Proc Natl Acad Sci 102 (2005) 5256-5261
119. Melville D.B., Horner W.H., Otken C.C., and Ludwig M.L. Studies of the origin of L-Ergo in animals. J Biol Chem 213 (1955) 61-68
120. Aruoma O.I., Spencer J.P., and Mahmood N. Protection against oxidative damage and cell death by the natural antioxidant ergothioneine. Food Chem Toxicol 37 (1999) 1043
121. Deiana M., Rosa A., Casu V., Piga R., Assunta Dessi M., and Aruima O.I. L-ergothioneine modulates oxidative damage in the kidney and liver of rats in vivo: studies upon the profile of polyunsaturated fatty acids. Clin Nutr 23 (2004) 183
122. Rahman I., Gilmour P.S., Jimenez L.A., Biswas S.K., Antonicelli F., and Aruoma O.I. Ergothioneine inhibits oxidative stress- and TNF-α-induced NF-κB activation and interleukin-8 release in alveolar epithelial cells. Biochem Biophys Res Commun 302 (2003) 860-864
123. Stoll M., Corneliussen B., Costello C.M., Waetzig G.H., Mellgard B., Koch W.A., et al. Genetic variantion in DLG5 is associated with inflammatory bowel disease. Nat Genet 36 (2004) 476-480
124. Gonzalez-Mariscal L., Betanzos A., and Avila-Flores A. MAGUK proteins: structure and role in the tight junction. Semin Cell Dev Biol 11 (2000) 315-324
125. Shah G., Brugada R., Gonzalez O., Czernuszewicz G., Gibbs R.A., Bachinski L., et al. The cloning, genomic organization and tissue expression profile of the human DLG5 gene. BMC Genomics 3 (2002) 6-12
126. Wakabayashi M, Ito T, Mitsushima M, Aizawa S, Ueda K, Amachi T, et al., Interaction of Ip-dlg/KIAA0583, a membrane-associated guanylate kinase family protein, with vinexin and beta-catenin at sites of cell-cell contact. J Biol Chem 2003;278:21709-14.
127. Hollander D. Crohn's disease-a permeability disorder of the tight junction. Gut 29 (1988) 1621-1624
128. Noble C.L., Nimmo E.R., Drummond H., Smith L., Arnott I.D., and Satsangi J. DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population. Gut 54 (2005) 1416-1420
129. Daly M.J., Pearce A.V., Farwell L., Fisher S.A., Latiano A., Prescott N.J., et al. Association of DLG5 R30Q variant with inflammatory bowel disease. Eur J Hum Genet 13 (2005) 835-839
130. Newman W.G., Gu X., Wintle R.F., Liu X., van Oene M., Amos C.I., et al. DLG5 variants contribute to Crohn's disease risk in a Canadian population. Hum Mut 27 (2006) 353-358
131. Stokkers P.C., Rectsma P.H., Tytgot G.N., and van Deventer S.J. HLA-DR and DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut 45 (1999) 395-401
132. Forcione D.G., Sands B., Isselbacher K.J., Rustgi A., Podolsky D.K., and Pillai S. An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele. Proc Natl Acad Sci USA 93 (1996) 5094-5098
133. Cariappa A., Sands B., Forcione D., Finkelstein D., Podolsky D.K., and Pillai S. Analysis of MHC class II DP, DQ, and DR alleles in Crohn's disease. Gut 43 (1998) 210-215
134. Ahmad T., Armuzzi A., Neville M., et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tiss Antigens 62 (2003) 527-535
135. Bouma G., Crusius J.B., Garcia-Gonzalez M.A., Meijer B.U., Hellemans H.P., Hakvoort R.J., et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol 115 (1999) 294-300
136. Roussomoustakaki M., Satsangi J., Welsh K., Louis E., Fanning G., Targan S., et al. Genetic markers may predict disease behaviour in patients with ulcerative colitis. Gastroenterology 112 (1997) 1845-1853
137. Silverberg M.S., Mirea L., Bull S.B., Murphy J.E., Steinhart A.H., Greenberg G.R., et al. A population- and family-based study of Canadian families reveals association of HLA DRB1*0103 with colonic involvement in inflammatory bowel disease. Inflamm Bowel Dis 9 (2003) 1-9
138. Orchard T.R., Chu C.N., Ahmed, Cheng H., Welsh K.I., and Jewell D.P. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 123 (2002) 714-718
139. Orchard T.R., Woodsworth B.P., and Jewell D.P. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42 (1998) 387-391
140. Kontoyiannis D., Pasparakis M., Pizarro T.T., Cominelli F., and Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10 (1999) 387-398
141. Targan S.R., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337 (1997) 1029-1035
142. Negoro K., Kinouchi Y., Hiwatashi N., Takahashi S., Takagi S., Satoh J., et al. Crohn's disease is associated with novel polymorphisms in the 5′-flanking region of the tumor necrosis factor gene. Gastroenterology 117 (1999) 1062-1068
143. van Heel D.A., Udalova I.A., De Silva A.P., McGovern D.P., Kinouchi Y., Hull J., et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. Hum Mol Genet 11 (2002) 1281-1289
144. O'Callaghan N.J., Adams E.M., van Heel D.A., and Cavanaugh J.A. Association of TNF-alpha-857C with inflammatory bowel disease in the Australian population. Scand J Gastroenterol 38 (2003) 533-534
145. Cantor M.J., Nickerson P., and Bernstein C.N. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am J Gastroenterol 100 (2005) 1134-1142
146. Waschke K.A., Villani A.C., Vermeire S., Dufresne L., Chen T.C., Bitton A., et al. Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotype. Am J Gastroenterol 100 (2005) 1126-1133
147. Karban A.S., Okazaki T., Panhuysen C.I., Gallegos T., Potter J.J., Bailey-Wilson J.E., et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 13 (2004) 35-45
148. McGovern D.P.B., Hysi P., Ahmad T., van Heel D.A., Moffatt M.F., Carey A., et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet 14 (2005) 1245-1250
149. Torok H.P., Glas J., Tonenchi L., Bruennler G., Folwaczny M., and Folwaczny C. Crohn's disease is associated with a toll-like recptor-9 polymorphism. Gastroenterology 127 (2004) 365-366
150. Rachmilewitz D., Katakura K., Karmeli F., Hayashi T., Reinus C., Rudensky B., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126 (2004) 520-528
151. Pierik M., Joossens S., Van Steen K., Van Schuerbeek N., Vlietinck R., Rutgeerts P., et al. Toll-like receptor-1, -2, and -6 polymorphisms influences disease extension in inflammatory bowel disease. Inflamm Bowel Dis 12 (2006) 1-8
152. Franchimont D., Vermeire S., El Housni H., Pierik M., Van Steen K., Gustot T., et al. Deficient host-bacteria interactions in inflammatory bowel disease. The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53 (2004) 987-992
153. Lakatos P.L., et al. Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World J Gastroenterol 11 (2005) 1489-1495
154. Gazouli M., Mantzaris G., Kotsinas A., Zacharatos P., Papalambros E., Archimandritis A., et al. Association between polymorphisms in the toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol 11 (2005) 681-685
155. Torok H.P., Glas J., Tonenchi L., Mussack T., and Folwaczny C. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 112 (2004) 85-91
156. Braat H., Stokkers P., Hommes T., Cohn D., Vogels E., Pronk I., et al. Consequence of functional Nod2 and Tlr4 mutations on gene transcription in Crohn's disease patients. J Mol Med 83 (2005) 601-609
157. Brand S., Staudinger T., Schnitzler F., Pfennig S., Hofbauer K., Dambacher J., et al. The role of toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 11 (2005) 645-652
158. Lorenz E., Mira J.P., Frees K.L., and Schwartz D.A. Relevance of mutations in the TLR4 receptor patients with gram-negative septic shock. Arch Intern Med 162 (2002) 1028-1032
159. Erridge C., Stewart J., and Poxton I.R. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutation in the Toll-like receptor 4 gene show no deficit in lipopolysaccaride signaling. J Exp Med 197 (2003) 1787-1791
160. Fries W., Renda M.C., Lo Presti M.A., Raso A., Orlando A., Oliva L., et al. Intestinal permeability and genetic determinants in patients, first-degree relatives, and controls in a high-incidence area of Crohn's disease in Southern Italy. Am J Gastroenterol 100 (2005) 2730-2736